Gastrointestinal Stromal Tumor (GIST) – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Gastrointestinal Stromal Tumor (GIST) – Pipeline Review, H1 2020’, provides an overview of the Gastrointestinal Stromal Tumor (GIST) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gastrointestinal Stromal Tumor (GIST), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastrointestinal Stromal Tumor (GIST) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (GIST)

– The report reviews pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Gastrointestinal Stromal Tumor (GIST) therapeutics and enlists all their major and minor projects

– The report assesses Gastrointestinal Stromal Tumor (GIST) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Gastrointestinal Stromal Tumor (GIST)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (GIST) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AB Science SA

ABL Bio Inc

Advenchen Laboratories LLC

Arog Pharmaceuticals Inc

Ascentage Pharma Group International

Bayer AG

Blueprint Medicines Corp

Calithera Biosciences Inc

Chipscreen Biosciences Ltd

CStone Pharmaceuticals Co Ltd

Daiichi Sankyo Co Ltd

Deciphera Pharmaceuticals Inc

Eisai Co Ltd

Eli Lilly and Co

Esperas Pharma Inc

Exelixis Inc

F. Hoffmann-La Roche Ltd

Hanmi Pharmaceuticals Co Ltd

Hefei Cosource Pharmaceutical Inc

Horizon Therapeutics Plc

Immunicum AB

ImmunityBio Inc

Ipsen SA

Jiangsu Hengrui Medicine Co Ltd

Karyopharm Therapeutics Inc

Marino Biotechnology Co Ltd

Merck & Co Inc

Merck KGaA

Ningbo Tai Kang Medical Technology Co Ltd

NMS Group SpA

Novartis AG

Omeros Corp

Pfizer Inc

Pharma Mar SA

Plexxikon Inc

Rhizen Pharmaceuticals SA

Sartar Therapeutics Ltd

Shanghai Haihe Biopharma Co Ltd

Shijiazhuang Yiling Pharmaceutical Co Ltd

Soricimed Biopharma Inc

Taiho Oncology Inc

Takeda Pharmaceutical Co Ltd

Xencor Inc

Table of Contents

Table of Contents

Introduction

Gastrointestinal Stromal Tumor - Overview

Gastrointestinal Stromal Tumor - Therapeutics Development

Gastrointestinal Stromal Tumor - Therapeutics Assessment

Gastrointestinal Stromal Tumor - Companies Involved in Therapeutics Development

Gastrointestinal Stromal Tumor - Drug Profiles

Gastrointestinal Stromal Tumor - Dormant Projects

Gastrointestinal Stromal Tumor - Discontinued Products

Gastrointestinal Stromal Tumor - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Gastrointestinal Stromal Tumor (GIST) – Pipeline by AB Science SA, H1 2020

Gastrointestinal Stromal Tumor (GIST) – Pipeline by ABL Bio Inc, H1 2020

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Advenchen Laboratories LLC, H1 2020

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Arog Pharmaceuticals Inc, H1 2020

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Ascentage Pharma Group International, H1 2020

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Bayer AG, H1 2020

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Blueprint Medicines Corp, H1 2020

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Calithera Biosciences Inc, H1 2020

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Chipscreen Biosciences Ltd, H1 2020

Gastrointestinal Stromal Tumor (GIST) – Pipeline by CStone Pharmaceuticals Co Ltd, H1 2020

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Daiichi Sankyo Co Ltd, H1 2020

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Deciphera Pharmaceuticals Inc, H1 2020

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Eisai Co Ltd, H1 2020

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Eli Lilly and Co, H1 2020

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Esperas Pharma Inc, H1 2020

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Exelixis Inc, H1 2020

Gastrointestinal Stromal Tumor (GIST) – Pipeline by F. Hoffmann-La Roche Ltd, H1 2020

Gastrointestinal Stromal Tumor (GIST) – Dormant Projects, H1 2020

Gastrointestinal Stromal Tumor (GIST) – Dormant Projects, H1 2020 (Contd..1), H1 2020

Gastrointestinal Stromal Tumor (GIST) – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports